Comments
Alembic Pharmaceuticals has received an Establishment Inspection Report from the US health regulator for its formulation facility located at Panelav in Gujarat.
“The company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at our formulation facility at Panelav during the period from March 12-20, 2018,” Alembic Pharmaceuticals said in a BSE filing today.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Alembic Pharma were trading up by 2.98 per cent at Rs 521.65 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.